PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 2010 March 16; 102(6): 1052–1060.
Published online 2010 March 2. doi:  10.1038/sj.bjc.6605591
PMCID: PMC2844039

The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells

Abstract

Background:

The G-protein-coupled formylpeptide receptor (FPR) that mediates chemotaxis of phagocytic leucocytes induced by bacterial and host-derived chemotactic peptides is selectively expressed by highly malignant human gliomas and contributes to tumour growth and angiogenesis. As invasion of surrounding normal tissues is one of the important features of tumour malignancy, we investigated the function of FPR in the invasive behaviour of human glioblastoma cells.

Methods:

Cells (FPR+ and FPR) were isolated by single-cell cloning from a human glioblastoma cell line U-87MG. The FPR expression was assayed by flow cytometry and reverse transcription PCR. The function of FPR was investigated by chemotaxis and calcium flux induced by FPR agonist fMLF. Tumour cell motility was assayed by a wound-healing model in vitro. The growth and invasive phenotype were observed with subcutaneous implantation of tumour cells in nude mice. Over-expression of FPR in FPR cells was performed by transfection of a plasmid vector-containing human FPR gene.

Results:

One of the glioma clones F9 that expressed high level of FPR showed a more ‘motile' phenotype in vitro as compared with a clone G3 without FPR expression. Although F9 and G3 clones both formed subcutaneous tumours in nude mice, only F9 tumours invaded surrounding mouse connective tissues. Over-expression of FPR in G3 clone (G3F) increased the cell motility in vitro and the capacity of the cells to form more rapidly growing and invasive tumours in nude mice. We further found that, in addition to supernatant of necrotic tumour cells, foetal calf serum and human serum used in culture media contained FPR agonist activity and increased the motility of FPR-expressing glioblastoma cells.

Conclusion:

The expression of FPR is responsible for increased motility of human glioblastoma cells and their formation of highly invasive tumours.

Keywords: formylpeptide receptor, invasion, glioblastoma, cancer

Malignant gliomas are diffuse, often multifocal and invasive tumours with a dismal prognosis. A major barrier to effective treatment of malignant gliomas is their tendency to extend tendrils of tumour away from the main tumour mass. In fact, 95% gliomas recur within 2.5 cm of the resection margin, which contains residual tumour cells that act as a ‘disease reservoir' (Giese et al, 2003). Malignant glioma cells acquire characteristic properties from a number of coordinated cellular programmes, including abberant expression of cell surface chemoattractant and growth-factor receptors, necessary for increased proliferation (e.g. expansion), migration (e.g. motility), invasion (e.g. extracellular matrix (ECM) degradation) (Demuth and Berens, 2004) and angiogenesis (e.g. production of angiogenic factors) (Giese et al, 2003).

Formylpeptide receptor (FPR) is a G-protein-coupled receptor (GPCR), originally identified in phagocytic leucocytes, that mediates cell chemotaxis and activation in response to the bacterial formylated chemotactic peptides (e.g. fMLF). Agonist binding to FPR elicits a signal transduction cascade involving phosphatidylinositol 3-kinase, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs) and the transcription-factor nuclear-factor (NF)-κB (Le et al, 2002; Cheng et al, 2007). Owing to its expression in cells of the immune system and its interaction with bacterial chemotactic peptides, FPR was thought to participate in host defence against microbial infection. In support of this notion, mice depleted of the FPR analogue mFPR1 were more susceptible to infection by Listeria monocytogenes (Gao et al, 1999) that produced high affinity mFPR1 agonist peptides (Southgate et al, 2008). Recently, a number of host-derived chemotactic agonists of FPR have been identified, including formylpeptides potentially released by mitochondria of ruptured cells (Rabiet et al, 2005), annexin I produced by activated epithelia (Xia et al, 2002) and a neutrophil granule protein, cathepsin G (Sun et al, 2004). In addition, functional FPR has been detected in cells of nonhaematopoietic origin, such as lung epithelial cells (Rescher et al, 2002) and hepatocytes (McCoy et al, 1995). These findings expanded the spectrum of pathophysiologic processes in which FPR may have a function.

As a support of the function for FPR in diseases other than anti-microbial host defence, our recent studies revealed that tumour cells of a majority of highly malignant human gliomas, including anaplastic astrocytoma (grade III) and glioblastoma multiforme (GBM, grade IV), express FPR (Zhou et al, 2005; Huang et al, 2008a). The FPR expressed in tumour cells derived from human GBM by responding to cognate agonist peptide fMLF and agonist(s) released by necrotic tumour cells promote the directional migration, survival and production of angiogenic factors by tumour cells (Zhou et al, 2005; Yao et al, 2008a). Depletion of FPR by short-interference RNA markedly reduced the tumourigenicity of GBM cells in immune-deficient mice (Zhou et al, 2005). Thus, both in vitro and in vivo evidence supports the potential for FPR to exacerbate the progression of highly malignant human glioma. As malignant tumours are composed of heterogeneous cells varying in their degree of differentiation or malignancy, and as increased motility and invasiveness define more highly malignant tumour cell subsets, we studied the contribution of FPR to the invasive capacity of human GBM cells. Here, we report that expression of FPR is sufficient to endow GBM cells with a more motile phenotype and with greater capacity to form tumours infiltrating surrounding normal tissues.

Materials and methods

Cells and reagents

Human GBM cell line U-87MG was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were grown in Dulbecco's modified Eagle medium (DMEM) containing 10% foetal calf serum (FCS) and antibiotics; fMLF was purchased from Sigma-Aldrich (St Louis, MO, USA). Antibodies against phosphorylated Akt, Akt, phosphorylated p38, p38, phosphorylated Erk, Erk, phosphorylated EGFR (tyrosine 992) and EGFR were from Cell Signaling Technology (Beverly, MA, USA). Antibodies against vimentin, glial fibrillary acidic protein (GFAP) and FPR were from BD Biosciences (San Jose, CA, USA).

Isolation of FPR-positive and -negative tumour cell clones

U-87MG cells were plated in 96-well plates at a concentration of a single cell per well. Wells containing either none or more than one cell were excluded for further analysis. After expansion of single-cell clones, the FPR+ and FPR subclones were identified by immunofluorescence staining of FPR, reverse transcription PCR (RT–PCR) and functional assays. One cell clone expressing high level of FPR was designated F9, whereas one clone, which was completely negative for FPR expression, was termed as G3.

Over-expression of FPR in G3 cells

G3 cells were transfected with the Superfect Transfection Reagent (QIAGEN, Valencia, CA, USA) and 5 μg FPR-expressing plasmid pcDNA3 or blank plasmid pcDNA3 (Invitrogen, Carlsbad, CA, USA). The FPR-transfected cells (G3F) and mock-transfected cells (G3M) were selected and maintained by incubation with 800 μg ml–1 antibiotic G418. G3F cells were selected by flow cytometry sorting after staining with a PE-conjugated monoclonal antibody against FPR.

Chemotaxis, Ca2+ flux and immunoblotting

Assays for tumour cell chemotaxis (Le et al, 2000; Zhou et al, 2005), Ca2+ mobilisation and immunoblotting were performed according to the described procedures (Le et al, 2000; Zhou et al, 2005).

Wound-healing assays

The wound-healing assays were performed according to the published procedures (Liang et al, 2007). Briefly, tumour cells were labelled either by CellTracker Red CMPTX or CellTracker Green CMFDA (Invitrogen). Equal number of labelled cells were mixed and planted in 6 cm culture dishes. When the cells reached confluence, a 1000 μl pipette tip (ThermoFisher Scientific, Waltham, MA, USA) was used to scratch and create a gap in the monolayer. Detached tumour cells were immediately removed by replacement of culture medium. The cell movement phase images were subsequently captured under light microscopy. The fluorescence time-lapse images were monitored by laser confocal microscopy. The results were quantified by calculating mean migrated distance of leading cells or the cell number filled in the scratched area (gate).

Adhesion assays

Flat-bottomed 96-well plates were coated with 0.5% gelatin or 30 μg ml–1 laminin at room temperature for 1 h followed by 1% heat-inactivated BSA for 30 min at room temperature. The plates were washed twice by PBS, and 100 μl of 4 × 105 per ml tumour cells were added to the wells. The plates were cultured for 10 min at 37°C and non-adherent cells were then removed by washing with ice-cold PBS. The number of adhering cells was evaluated by MTT method according to the kit manual (Sigma-Aldrich). The percentage of adhered cells in total input cells was calculated as the rate of adhesion.

Zymography for MMP expression

Zymography (gelatin-substrate gel electrophoresis) was performed according to the described methods (Zhou et al, 2002) and the manual of the Zymography system (Invitrogen).

Vascular endothelial growth factor production and microvascular density

Vascular endothelial growth factor (VEGF) in the supernatants of tumour cells was quantified by commercial enzyme-linked immunosorbent assay kits (Lymphokine Testing Laboratory, SAIC Frederick, Frederick, MD, USA). Frozen sections of xenograft tumours were stained with anti-human VEGF and PE-labelled second antibodies to visualise the VEGF expression, with anti-CD105 antibodies (Biolegend, San Diego, CA, USA) and immunochemical staining kit (LabVision, Fremont, CA, USA) to visualise the microvasculature.

Flow cytometry, RT–PCR, immunocytochemistry tumourigenesis, histology, cell proliferation and tumour colony formation

Flow cytometry, RT–PCR, immunocytochemistry tumourigenesis, histology, cell proliferation and tumour colony formation were performed as reported earlier (Huang et al, 2007, 2008b).

Statistical analyses

All experiments were performed at least three times and representative results are shown. A computer-aided Mann–Whitney U-test program SPSS (Version 11.0) (GraphPad Software Inc., San Diego, CA, USA) was used to determine the statistical significance of the differences between cell responses to testing materials and controls in experiments of chemotaxis, cell proliferation, adhesion, tumour colony formation and growth in nude mice.

Results

Isolation of FPR-positive and -negative subsets from U-87MG cells

Despite the high proportion of FPR-expressing cells in U-87MG cell line, it also contained subsets that were negative for FPR. By single-cell cloning, we isolated an F9 subclone that expressed high level of FPR at both protein and mRNA levels. In contrast, a G3 subclone was entirely negative for FPR (Figure 1A and B). Functionally, the FPR agonist fMLF induced robust chemotaxis and calcium flux responses in F9 cells, but not in G3 cells (Figure 1C). As reported (Zhou et al, 2005; Huang et al, 2007), fMLF also induced the phosphorylation of MAPKs, Akt and EGFR in F9, but not G3, cells (Figure 1D). After at least 15 passages, both F9 and G3 cells maintained their FPR-positive and -negative states, respectively.

Figure 1
The FPR expression and function in FPR+ and FPR subclones from human U-87MG glioblastoma cells. Clones (FPR+ (F9) and FPR (G3)) were isolated by single-cell clone. (A) FACS analysis of FPR expression on tumour cells. ...

Phenotype of FPR+ and FPR subclones

Both F9 and G3 subclones expressed vimentin, a marker for astroglial cell precursors, with lower levels in the FPR G3 cell subclone. As compared with F9 cells, G3 cells expressed a higher level of GFAP, a glial differentiation maker (Figure 2A), suggesting that although both subclones were from a GBM cell line, the FPR+ clone F9 was more poorly differentiated as compared with the FPR clone G3.

Figure 2
Morphology and motility of F9 and G3 cells. (A) Analysis of the expression of GFAP and vimentin in F9 and G3 cells. Anti-vimentin and GFAP antibodies were used to label F9 and G3 cells. The proteins were visualised (green) by an FITC-conjugated secondary ...

We next compared the mobility of FPR+ F9 and FPR G3 cells in a wound-healing model by creating a gap in a confluent cell monolayer. We found that the FPR+ F9 cells moved more rapidly than the FPR G3 cells to fill the gap in the cell monolayer (Figure 2B). In nude mice, although both subclones formed tumours, only the FPR+ F9 tumours invaded the surrounding mouse connective tissues with disruption of the dermis. In contrast, tumours formed by G3 cells were encapsulated by intact fibrous membrane without apparent invasion of normal mouse tissues by tumour (Figure 2C). These results indicate that in a heterogeneous human GBM cell line, the FPR+ cells exhibit a more motile and invasive behaviour as compared with FPR counterpart cells.

Enhanced FPR+ cell motility and adhesion in vitro

To more precisely study the contribution of FPR to tumour cell motility and invasiveness, we transfected FPR into FPR G3 cells. Flow cytometry confirmed FPR expression in transfected G3 cells (G3F), but not in mock-transfected G3 cells (G3M) (Supplementary Figure 1A). Functionally, FPR agonist fMLF induced chemotaxis, calcium flux (Supplementary Figure 1B) and phosphorylation of Erk1/2 and p38 MAPKs as well as Akt in G3F cells (Supplementary Figure 1C). Stimulation of FPR in G3F cells also transactivated EGFR by inducing phosphorylation of the tyrosine residue 992 (Supplementary Figure 1C). Thus, transfection of FPR in an FPR subclone of GBM line enabled these cells to exhibit full agonist-induced responses as shown by tumour cells constitutively expressing FPR (Zhou et al, 2005; Huang et al, 2007).

We then measured the motility of G3F and G3M cells in the wound-healing model in vitro. As shown in Figure 3A and B, G3F cells labelled with green fluorescence showed more rapid locomotion than G3M cells towards the centre of the gap created on cell monolayer in the presence of 100 nM fMLF or 10% human serum (HS). A time-lapse imaging of the migration in the ‘wound' of G3F and G3M cells in medium with 10% HS is shown in Supplementary Movie 1. In addition, G3F and F9 cells cultured in 100 nM fMLF and 10% HS showed increased adhesion on gelatin- and laminin-coated plastic than their respective control G3M and G3 cells (Figure 3C). These results confirm that FPR expression enables GBM cells to exhibit higher level of motility and adhesion in the presence of FPR agonist fMLF or HS.

Figure 3
The GBM cell motility and adhesion in vitro. (A, B) Cell motility. The motility of CMPTX-labelled G3M (red) and CMFDA-labelled G3F (green) in wound-healing model were assayed in the presence of 100 nM fMLF or 10% HS by time-lapse photographing ...

MMP production and growth of G3F cells in vitro

As increased production of MMP2 and MMP9 is associated with tumour invasion, we examined the capacity of G3F cells to produce the enzymes that are implicated in the breakdown of basement membrane by invading tumour cells. As shown in Figure 4A, the mRNA levels of MMP2 and MMP9 in G3F cells were increased when the cells were stimulated with the FPR agonist or cultured in the presence of HS. Zymography of conditioned media revealed that the levels of soluble pro-MMP-2 protein from G3F cells were higher than G3M cells (Figure 4B). In addition, fMLF increased the level of pro-MMP2 released by G3F cells. Moreover, the active MMP2 produced by G3F cells was at a higher level than that produced by G3M cells despite the absence of fMLF or HS in cell culture. We further found that G3 cells over-expressing FPR (G3F) grew more rapidly (Figure 4C) and they formed more large-size tumour colonies in soft agar (Figure 4D) as compared with mock-transfected cells G3M.

Figure 4
The MMP expression and cell growth in vitro. (A) Expression of MMP2 and MMP9. G3F cells were cultured in the presence or absence of fMLF or 10% HS for 24 h at 37°C, followed by RT–PCR detection of mRNA for MMP2 and MMP9. ...

Increased tumourigenesis, invasiveness and angiogenesis in tumours formed by G3F cells

On the basis of in vitro findings that over-expression of FPR in G3 GBM subset cells transformed the cells into a more invasive and proliferative phenotype, we injected the tumour cells subcutaneously into the flanks of athymic mice and measured the rate of tumourigenesis. Tumours formed by G3F cells grew more rapidly than those formed by the wild-type or mock-transfected G3 cells (Figure 5A). Histological examination showed tumours formed by G3F cells penetrated the dermis and invaded the surrounding mouse connective tissues. In contrast, G3M tumours grew more slowly and were surrounded by intact dermis (Figure 5B).

Figure 5
Tumourigenesis, invasiveness and angiogenesis. (A) Tumourigenesis in nude mice. Wild-type G3 (G3WT), G3M and G3F cells at 5 × 106 cells in 100 μl of PBS per mouse were injected subcutaneously into the flanks of athymic mice. Tumour ...

We then measured VEGF production by U-87MG subclones in vitro and the density of microvessles in xenograft tumours. Stimulation of G3F, F9 cells and the parental U-87MG cells with the FPR agonist fMLF increased their production of VEGF (Figure 5C). The increased production of VEGF by FPR-expressing G3F cells in vitro was corroborated by significantly increased VEGF production and the microvessels in tumours formed by these cells as shown in Figure 5D. Thus, FPR expression is sufficient to promote the growth, invasion and angiogenesis of tumour cells, which were originally FPR negative and had a lesser degree of malignancy.

Identification of potentially endogenous source of FPR agonist activity

We earlier observed that the supernatants of necrotic U-87MG cells and xenograft tumour tissues of glioma cells contained FPR agonist activity (Zhou et al, 2005), thus may represent an endogenous source of FPR ligands in the tumour microenvironment. As FPR+ GBM cell clones exhibited increased motility in vitro in serum-containing media without the addition of exogenous FPR agonists, we examined the possibility of the presence of FPR agonists in culture media. We found that both FCS and HS were able to induce migration of GBM cell subsets in vitro and the FPR-expressing F9 and G3F cells showed higher levels of cell migration in response to serum-containing media as compared with the G3 and G3M counterparts, respectively (Figure 6A–C). The tumour cell migration inducing activity of FCS or HP was composed mainly of chemotactic with minor, but significant contribution of the chemokinetic element as measured by checkerboard analyses (Supplementary Table 1) in which tumour cells also migrated in the presence of negative serum gradients or equal serum concentrations in both upper and lower wells of the chemotaxis chambers. Importantly, the migration of FPR+ tumour cells induced by FCS or HS was partially and significantly inhibited by an FPR-specific antagonist cyclosporine H (CsH) (Wenzel-Seifert and Seifert, 1993; De Paulis et al, 1996), which had no effect on EGF-induced tumour cell migration (Figure 6B and C), suggesting the presence of FPR agonist(s) in FCS and HS. The HS also induced a robust intracellular Ca2+ mobilisation in G3F cells (Figure 6D) and attenuated the subsequent cell response to fMLF (Figure 6D). Conversely, fMLF also significantly desensitised HS-induced Ca2+ mobilisation in G3F cells (Figure 6D). These results indicate the presence of FPR agonists in FCS and HS and provide a basis for the increased motility of FPR+ tumour cells in the absence of the defined FPR agonists fMLF. Thus, tumour cells may take advantage of the presence of FPR agonists in both necrotic tumour supernatants and in normal serum to promote their growth, invasion and angiogenesis.

Figure 6
The FPR agonist activity in FCS and HS. (A) FCS-induced migration of F9 and G3 cells. F9 or G3 cells were measured for migratory response to 10% FCS. *Indicates significantly increased migration of F9 cells in response to FCS as compared ...

Discussion

Human gliomas are heterogeneous in their degree of malignancy, ranging from more slowly growing astrocytoma to fast growing and highly invasive GBM. This study showed that even in a well-established GBM cell line, FPR is expressed at different levels by cell subsets, and an FPR-expressing subset is more motile and forms more rapidly growing invasive tumours in nude mice as compared with its FPR-negative counterpart. The FPR-expressing clone F9 also expressed higher levels of vimentin, an astroglia precursor marker, but lower levels of the differentiation marker GFAP than the FPR-negative subset G3. This is consistent with the findings with surgically removed human glioma specimens, in which FPR expression is associated with poorly differentiated tumours, and within individual human gliomas, tumour cells frequently exhibit remarkable heterogeneity (Zhou et al, 2005). This may explain our findings that 3 out of 14 anaplastic astrocytoma were negative for FPR and 2 out of 13 of less invasive astrocytoma are positive for FPR (Zhou et al, 2005). The presence of highly proliferative and invasive cell populations in a given solid tumour determines the rate of tumour progression and the lethality to the host. The U87 glioblastoma cell line contains both FPR+ and FPR subpopulations: although the FPR+ subpopulation represented by F9 clone, the G3 subclone is FPR as reported in this study. However, both the FPR+ F9 subclone and the FPR G3 subclone express EGF receptor and proliferate in response to EGF. Therefore, in the heterogeneous U87 cell line, the FPR+ cells did not show apparent growth advantage over FPR cells in vitro. This may explain why FPR cells may sustain their growth over longitudinal passaging and are uncoverable in the heterogeneous population. The FPR gene has a single copy in FPR+ U87 cells. Over a period of 15 passages, these FPR+ cells represented by the F9 clone maintained the same level of FPR expression. However, it is interesting to note that it has been reported that glioma stem-like cells isolated from U87 cell line and primary human gliomas express FPR (Yao et al, 2008b) and such stem-like cells differentiate in vitro to yield both FPR+ and FPR descendents. Therefore, it seems that FPR+ malignant glioma cells may represent a more poorly differentiated cell population with higher degree of malignancy.

One of the most important features of malignant tumour cells is their capacity to break the barrier of surrounding normal host tissues. This invasion process is known to depend not only on tumour cell motility, but also on tumour cell-secreted MMPs to degrade ECM. The MMPs also cleave and activate other growth factors such as TGF-β that are implicated in GBM motility and proliferation.

The expression of MMPs in tumour cells is induced by cytokines, growth factors, tumour promoters, physical stress, oncogenic transformation, and cell–matrix and cell–cell interactions. Several MMP genes are inducible by extracellular stimuli, which activate the AP1 transcription-factor complex through pathways involving MAPKs (ERK1/22, JNKs and p38) and PKC; PKC is also known to have a function in increasing MMP9 expression by malignant glioma cells (Yabkowitz et al, 1999) through cytoskeletal changes and NF-κB (Chintala et al, 1998). Activation of FPR in myeloid and GBM cells triggers these signalling events (Zhou et al, 2005; Kam et al, 2007); therefore, provide mechanistic basis for its ability to regulate the production and activation of MMPs. The capacity to mediate MMP production may be a common feature for chemoattractant GPCRs. For instance, an FPR variant receptor, FPRL1, in monocytic cells (Lee et al, 2005) and a chemokine GPCR CXCR3 in colon cancer cells have also been shown to up-regulate MMP9 (Zipin-Roitman et al, 2007). Thus, GPCRs have an important function in increasing the proteolytic processes favouring leucocyte infiltration of tissues and tumour dissemination.

Progression of malignant tumours depends on timely neovascularisation in tumour and surrounding tissues. One of the most potent angiogenic factors produced in solid tumours is VEGF, which not only acts on vascular endothelial cells, but also increases the survival, migration and invasion of many tumour cells bearing VEGF receptors. In addition, VEGF is a potent suppressor of antigen-presenting cells in tumour microenviroment, contributing to the establishment of immune privilege of tumours. Malignant gliomas, notably GBMs, are characterised by vigorous angiogenesis and the production of copious amounts of VEGF. Our earlier study showed that stimulation of FPR in human GBM cells increased cell production of VEGF (Zhou et al, 2005) and another angiogenic chemokine IL8 (CXCL8) (Yao et al, 2008a). This study indicates that expression of FPR alone in originally FPR-negative tumour cells is sufficient for tumour cells to produce VEGF in conventional culture conditions in the presence of FCS or HS, and stimulation with FPR agonist peptide fMLF further increased VEGF production. The more vigorous angiogenesis by FPR+ GBM cells was further shown by higher microvessel density in tumours formed by such tumour cells, indicating a pivotal function of FPR in enhancing the angiogenic and vasculogenic process in GBM. It is interesting to note that MMPs have been reported to also act as ‘angiogenic switch' in tumour neovascularisation (Bergers et al, 2000). Thus, FPR may promote GBM angiogenesis through direct induction of angiogenic factors and through elevated MMPs in tumour microenvironment.

Our study showing FPR agonist activity in the serum and supernatants of necrotic tumour cells (Zhou et al, 2005) strongly suggests that this receptor expressed by GBM cells may interact with host-derived agonists in vivo. Although the precise chemical nature of FPR agonist(s) contained in serum and necrotic tumour supernatants remains to be clarified, our preliminary results suggest that the FPR agonists are of small molecule peptide nature (Zhou et al, 2005). Plasma is the most complex human-derived proteome known to contain proteins derived from blood cells and other tissues including those released by normal or damaged cells and aberrant proteins from tumour cells. As proteins in the circulatory system are exposed to a variety of proteases and peptidases, plasma is rich in peptides of various size to constitute ‘peptidome'. In this context, some endogeneous agonists of FPR and its variant receptors have been identified, such as the neutrophil granule protein cathepsin G (Sun et al, 2004), cleaved peptide from urokinase plasminogen activator receptor (Resnati et al, 2002), a fragment of heme-binding proteins (F2L) (Migeotte et al, 2005) and formylated peptides from mitochondria (Rabiet et al, 2005). In addition, a phospholipid-binding protein annexin I, which was reported to be a ligand for FPR and its variant receptors, has been implicated in promoting the invasiveness of a human intestinal cancer cell line and a mouse melanoma cell line (Babbin et al, 2006; Rondepierre et al, 2009). Although the molecular nature of the FPR-stimulating activity in sera remains to be elucidated, our further studies showed that the chemotactic activity and colony-stimulating activity contained in the supernatant of necrotic GBM cells were depleted by immunoabsorption with an antibody against annexin I (Yang et al, manuscript in preparation), suggesting that annexin I is likely a major component responsible for the FPR-stimulating activity released by necrotic GBM cells. Thus, identification and characterisation of FPR agonist(s) in human GBM tissues, which may activate the receptor on tumour cells will shed light on the mechanisms of tumour–microenvironment interaction.

In summary, malignant tumours exploit their microenvironment to favour their survival, growth, invasion of fertile ‘soil', and angiogenesis by ‘hijacking' receptors involved in physiological processes to sense agonists present in the intercellular milieu. The FPR behaves as an oncoprotein that confers a highly malignant phenotype on GBM cells with increased cell motility, adhesion and release of proteases and production of angiogenic factors. Our recent study (Huang et al, 2008b) found that the aberrant expression of FPR in highly malignant GBM cells is closely associated with increased methylation of the p53 tumour suppressor gene promoter that reduced the capacity of p53 to repress the active transcription of FPR gene. Consequently, treatment of FPR-expressing GBM cells with methyltransferase inhibitor or transfection of the wild-type p53 reduced FPR expression and promoted GBM cell differentiation. Thus, studies of the regulation and signal transduction of FPR in GBM may yield novel molecular targets for anti-glioma therapy.

Supplementary Material

Supplementary Figure 1 and Table 1:
Supplementary Movie 1:

Acknowledgments

We thank Dr Joost J Oppenheim for reviewing the manuscript and Ms Cheryl N Magers and Ms Cheryl F Lamb for secretarial assistance. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organisations implies endorsement by the US Government. This project has been funded in part with federal funds from the National Cancer Institutes, National Institutes of Health, under Contract No. NO1-CO-12400. The research was also supported in part by the Intramural Research Program of the NCI, NIH and National Natural Science foundation of China (NSFC, No. 30973446). Animal care was provided in accordance with the procedures outlined in the ‘Guide for Care and Use of Laboratory Animals' (National Research Council; 1996; National Academy Press; Washington, D.C.).

Notes

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

References

  • Babbin BA, Lee WY, Parkos CA, Winfree LM, Akyildiz A, Perretti M, Nusrat A. Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors. J Biol Chem. 2006;281 28:19588–19599. [PubMed]
  • Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2 10:737–744. [PMC free article] [PubMed]
  • Cheng N, He R, Tian J, Dinauer MC, Ye RD. A critical role of protein kinase C delta activation loop phosphorylation in formyl-methionyl-leucyl-phenylalanine-induced phosphorylation of p47(phox) and rapid activation of nicotinamide adenine dinucleotide phosphate oxidase. J Immunol. 2007;179 11:7720–7728. [PubMed]
  • Chintala SK, Sawaya R, Aggarwal BB, Majumder S, Giri DK, Kyritsis AP, Gokaslan ZL, Rao JS. Induction of matrix metalloproteinase-9 requires a polymerized actin cytoskeleton in human malignant glioma cells. J Biol Chem. 1998;273 22:13545–13551. [PubMed]
  • De Paulis A, Ciccarelli A, de Crescenzo G, Cirillo R, Patella V, Marone G. Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine. J Allergy Clin Immunol. 1996;98 1:152–164. [PubMed]
  • Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 2004;70 2:217–228. [PubMed]
  • Gao JL, Lee EJ, Murphy PM. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J Exp Med. 1999;189 4:657–662. [PMC free article] [PubMed]
  • Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21 8:1624–1636. [PubMed]
  • Huang J, Chen K, Gong W, Zhou Y, Le Y, Bian X, Wang JM. Receptor ‘hijacking' by malignant glioma cells: a tactic for tumor progression. Cancer Lett. 2008a;267 2:254–261. [PubMed]
  • Huang J, Chen K, Huang J, Gong W, Dunlop NM, Howard OM, Bian X, Gao Y, Wang JM. Regulation of the leukocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis. 2008b;30 2:348–355. [PMC free article] [PubMed]
  • Huang J, Hu J, Bian X, Chen K, Gong W, Dunlop NM, Howard OM, Wang JM. Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells. Cancer Res. 2007;67 12:5906–5913. [PubMed]
  • Kam AY, Liu AM, Wong YH. Formyl peptide-receptor like-1 requires lipid raft and extracellular signal-regulated protein kinase to activate inhibitor-kappa B kinase in human U87 astrocytoma cells. J Neurochem. 2007;103 4:1553–1566. [PubMed]
  • Le Y, Hu J, Gong W, Shen W, Li B, Dunlop NM, Halverson DO, Blair DG, Wang JM. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J Neuroimmunol. 2000;111 1–2:102–108. [PubMed]
  • Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. 2002;23 11:541–548. [PubMed]
  • Lee HY, Kim MK, Park KS, Bae YH, Yun J, Park JI, Kwak JY, Bae YS. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun. 2005;330 3:989–998. [PubMed]
  • Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2 2:329–333. [PubMed]
  • McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA, Perlmutter DH. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J Exp Med. 1995;182 1:207–217. [PMC free article] [PubMed]
  • Migeotte I, Riboldi E, Franssen JD, Gregoire F, Loison C, Wittamer V, Detheux M, Robberecht P, Costagliola S, Vassart G, Sozzani S, Parmentier M, Communi D. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J Exp Med. 2005;201 1:83–93. [PMC free article] [PubMed]
  • Rabiet MJ, Huet E, Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol. 2005;35 8:2486–2495. [PubMed]
  • Rescher U, Danielczyk A, Markoff A, Gerke V. Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells. J Immunol. 2002;169 3:1500–1504. [PubMed]
  • Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 2002;99 3:1359–1364. [PubMed]
  • Rondepierre F, Bouchon B, Papon J, Bonnet-Duquennoy M, Kintossou R, Moins N, Maublant J, Madelmont JC, D'Incan M, Degoul F. Proteomic studies of B16 lines: involvement of annexin A1 in melanoma dissemination. Biochim Biophys Acta. 2009;1794 1:61–69. [PubMed]
  • Southgate EL, He RL, Gao JL, Murphy PM, Nanamori M, Ye RD. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol. 2008;181 2:1429–1437. [PMC free article] [PubMed]
  • Sun R, Iribarren P, Zhang N, Zhou Y, Gong W, Cho EH, Lockett S, Chertov O, Bednar F, Rogers TJ, Oppenheim JJ, Wang JM. Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J Immunol. 2004;173 1:428–436. [PubMed]
  • Wenzel-Seifert K, Seifert R. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L- leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E. J Immunol. 1993;150 10:4591–4599. [PubMed]
  • Xia SH, Hu LP, Hu H, Ying WT, Xu X, Cai Y, Han YL, Chen BS, Wei F, Qian XH, Cai YY, Shen Y, Wu M, Wang MR. Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene. 2002;21 43:6641–6648. [PubMed]
  • Yabkowitz R, Meyer S, Black T, Elliott G, Merewether LA, Yamane HK. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood. 1999;93 6:1969–1979. [PubMed]
  • Yao XH, Ping YF, Chen JH, Chen DL, Xu CP, Zheng J, Wang JM, Bian XW. Production of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPR. J Neurooncol. 2008a;86 1:47–53. [PubMed]
  • Yao XH, Ping YF, Chen JH, Xu CP, Chen DL, Zhang R, Wang JM, Bian XW. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol. 2008b;215 4:369–376. [PubMed]
  • Zhou Y, Bian X, Le Y, Gong W, Hu J, Zhang X, Wang L, Iribarren P, Salcedo R, Howard OM, Farrar W, Wang JM. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer Inst. 2005;97 11:823–835. [PubMed]
  • Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277 51:49481–49487. [PubMed]
  • Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 2007;67 7:3396–3405. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK